Skip to content
by Legal Desire
21 December 2020

DLA Piper advises Arlington Capital Partners in majority investment in Everest Clinical Research Corporation

Advising firms

Deal team

18 lawyers named
LawyerFirmSeniorityPracticeOffice
Jeffrey Houle Lead DLA Piper Partner Aerospace, Defense and Government Services Transactional Washington, DC
Russel Drew DLA Piper Partner Not stated Toronto
Thomas Pilkerton DLA Piper Partner Not stated Baltimore
Paolo Morante DLA Piper Partner Not stated New York
Christopher Mikson DLA Piper Partner Not stated Philadelphia
David Spratley DLA Piper Partner Not stated Vancouver
Veronica Monteiro DLA Piper Partner Not stated Edmonton
Qiang Li DLA Piper Partner Not stated Shanghai
Nia Brown DLA Piper Of counsel Not stated Washington, DC
Allen Xu DLA Piper Other Not stated Beijing
Ying Li DLA Piper Other Not stated Shanghai
Fangfang Song DLA Piper Other Not stated Beijing
Yiyuan Zhang DLA Piper Other Not stated Shanghai
Frank Chen DLA Piper Other Not stated Shanghai
Tina Xia DLA Piper Other Not stated Hong Kong
Mackenzie Clark DLA Piper Associate Not stated Toronto
Lauren Storwick DLA Piper Associate Not stated Calgary
Jordan Dugas DLA Piper Associate Not stated Edmonton

Stated terms

Stated value
Not stated
What the figure measures
Not stated
Client
Arlington Capital PartnersInvestor
Counterparties
Everest Clinical Research Corporation (Target)